Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMCISION II in advanced oral cavity squamous cell carcinoma
2025-522500-24-00Phase 3Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab and ipilimumab in Oral Mucosal Carcinoma and head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Complete clinical response with organ preservation at 24 months and Recurrence-free survival non-inferiority. Planned start Jan 2026; status: authorised.
02
Drugs
nivolumabipilimumab
03
Conditions
Oral Mucosal Carcinomahead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2025-522500-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522500-24-00.